| Biomarker ID | 908 |
| PMID | 22542564 |
| Year | 2012 |
| Biomarker | (percent free PSA) % fPSA |
| Biomarker Basis | Concentration Based (pg/ml) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Downregulated in PCa [No PCa: 19.36 ; PCa: 15.41; HGPIN: 22.23] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include (KLK3) :-ID regulation of gene expression,Prostate cancer, Androgen receptor proteolysis and transcription regulation, Androgen receptor signaling, proteolysis, and transcription regulation, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
| Experiment | PCa VS No PCa group; PCa Vs HGPIN group |
| Type of Biomarker | Diagnostic |
| Cohort | 67 patients with Benign Prostatic Hyperplasia, 36 with High Grade PIN, and 48 with Prostate Cancer were selected for the study. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | No PCa Vs PCa:p=0.004; PCa Vs HGPIN: p<0.001 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | KLK3 |